Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
thought that was you - I will eventually provide a list of links that I think will be of help to have at our finger tips.
It's not the company - because that would be inside information - probably a bogus call from the same person that called you last week pretending that it was the company.
********** MERRY CHRISTMAS EVERYONE ***********
Every year, on Christmas Eve, I watch "A Christmas Carol - Scrooge" and cry my eyes out.
My favorite, by far, is the 1951? version with Alastair Sim, and I always take out the DVD from the library a few days before Xmas... this year I forgot, and the only one played on TV is a version I don't particularly care for.
BUT... many thanks to YouTube for uploading my favorite version... and boy is it high quality... much better than the DVD was.
If you've never seen it... I highly recommend it.
Enjoy
Updated Spread Sheet - to Dec 8, 2017
I'm quite happy with $5,980,000 for 4th Quarter Seroquel Sales - going forward, that is approximately $24 Million, at least, in sales for the first year - not bad I think.
What I'm not sure I'll be happy with is IPCI's portion of those sales... if less than $2.4 million for 4th quarter, then I will be very unhappy with the royalty percentage they negotiated.
I can understand the low %age on Focalin since that was financed by PAR but if they are not getting 40% royalties on a product that was brought all the way through FDA approval on IPCI's dime... then they got F$%&^#.
I agree with Tilator... selling generics is not the same as selling NDA drugs.
I would have rather they did a 10 million share offering when their stock was above $3, and raised $30 million... that would have been more than enough to get the ball rolling and develop relationships with the few major distributors... they could have sold the generics for 30% to 40% less than everybody else and still would have made much more than if not getting 40% in royalties.
We'll see what is what at next earnings, mid February???
p.s. - thanxs for the #s fred... much easier to get a feeling for what-is-what when organized into a chart.
Fred, if you provide me with the $ Sales #s for these same dates I'll bring the SS up to date.
Also Monthly (Oct , Nov) $ sales #s for Seroquel and Focalin I am missing.
One picture is worth many words
* NEWS FLASH * NEWS FLASH * NEWS FLASH * NEWS FLASH * NEWS FLASH * NEWS FLASH * NEWS FLASH *
Dr Odidi slams his F#$%@^ Lamborghini into a wall - killed instantly... everyone here got what they wanted... a new CEO !!!
So where does IPCI open up in the morning... at $2.00 where all the suffering longs can get out... or at 25 F#$%@^ cents ????
Be careful what you wish for.
All of the above from a fantasy world... where all the other posts come from of late.
ANGELO FOCA 20F 271,000 0.80%
PENNA DOMENIC DELLA 20F 173,700 0.50%
ALLPORT JOHN NEWELL 20F 110,558 0.32%
YAT PATRICK NAJUM 20F 27,172 0.08%
SMITH ELDON R 20F 21,731 0.06%
MADHANI BAHADUR 20F 7,507 0.02%
Figured I'd help to bring it up-to-date.
Please add this useful link to the intro section
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
When I was a moderator on this board I had begun organizing the intro section by adding some useful links, so that certain information and/or utilities would be readily accessible.
Recently it has become in total disarray... some links have been unattached and others completely deleted.
I have no idea which moderator is responsible for that... I assume that they intended to add usefulness to the intro but got in over their heads... and didn't know what they were doing - if that is the case, I would like to see that person responsible delve deeper into understanding how the html coding works and bring back the bare essential functionality it had.
You can start by re-linking the Pipeline Chart which I referred to often... and the link to the FDA web site.
I'm all confused... drug prices and health insurance always make my head feel like it's going to blow up.
https://www.goodrx.com/venlafaxine
https://www.goodrx.com/venlafaxine-er
how can the extended release cost less??? and why is there a generic Effexor when Effexor has been discontinued???
If you hear a sudden POP... it's my brains splattering all over the walls.
I don't think that the comparison is appropriate.
Metformin is the basic generic that every tom dick and harry that has a simple pill press can turn out - 10 cents a pill is common going rate for that.
Glucophage XR is a much more complicated Extended Release formulation... not likely 10 cents a pill... my guess at least 50 cents a pill.
Also... I don't think it's simply a matter of producing and selling to tilator... before they do that tilator would have to demonstrate he has liability insurance to cover any law suits that may arise from improper storage and handling of the stuff... and who knows what other requirements there are... my guess of course.
The bonus plan was put in place years before it was awarded... and likely on the first ANDA approval as opposed to Keppra in specific... and I think it's quite normal to offer a reward for a milestone "first ANDA approval".
However, Samsa keeps implying that a bonus of $1.5 million will be paid out for every ANDA achieved... I keep asking if he knows this for a fact or just guessing at it... but have never got a straight answer.
Likewise, Samsa keeps implying that IPCI pays a yearly fee to keep the ANDAs open at the FDA... I don't believe such is the case... but have yet to get a definitive answer as to whether he knows this as fact or is it just an assumption on his part.
Does anybody know for sure??? perhaps Sevag can ask that at the meeting next Wednesday.
So that big block of 190+K which was sitting at .8111 on NSDQ on Monday and which had picked up a few thousand shares there... then on Tuesday moved over to EDGX sitting at the bid of .8222 for 187,300 where it picked up 300 shares... and is today sitting with a bid of .8333 on 187,000 shares... weird... +.0111 added per day and barely picking up a few hundred shares... will it be bidding .8444 tomorrow??? can't wait to see.
At that rate we should be up a quarter per month... and hopefully he never gets filled LOL
Intellipharmaceutics Announces Receipt of Nasdaq Notice
8:00 am ET December 5, 2017 (Globe Newswire) Print
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled- and targeted-release oral solid dosage drugs, announced today that it has received written notification (the "Notification Letter") from the The NASDAQ Stock Market LLC ("Nasdaq") notifying the Company that the minimum bid price per share for its common shares was below $1.00 for a period of 30 consecutive business days and that the Company did not meet the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Notification Letter does not impact the Company's listing on The Nasdaq Capital Market at this time.
The Company has a compliance period of 180 calendar days, or until June 4, 2018, to regain compliance with Nasdaq's minimum bid price requirement. To regain compliance, the Company's common shares must have a closing bid price of at least $1.00 for a minimum of 10 consecutive business days. The Company will work to regain compliance during the 180-day compliance period. In the event the Company does not regain compliance by June 4, 2018, the Company may be eligible for additional time to regain compliance.
As previously announced on September 20, 2017, the Company received written notice from Nasdaq indicating that the Company did not meet the minimum market value of listed securities requirement as set forth in Nasdaq Listing Rule 5550(b)(2).
We need a closing price of $1.01 for 10 days running to meet both $1.00 and $35 million minimum NSDQ compliance
the big block is still sitting at .8222 with 100 shares in the hand and 187,200 shares in the bush... but there's heavy trading above him... I think it's another fund buying in.
There is a block of 100K at $1.00 ask... hopefully he gets taken out by the end of the day.
that block bid for 187,300 at .8111 is now 187,200 at .8222 rather than .8111 - and 100 shares less so he got 100 shares by raising the bid but it ran away from him.
my guess .86+ close
Excellent post Fabius.
I'm not quite sure I remember this right... but I believe that the agreement between PAR and IPCI in regards to Focalin was "non-exclusive"
That is - PAR can manufacture and distribute Focalin XR independent of IPCI... and IPCI can also manufacture and distribute Focalin XR independent of PAR.
Does anybody else remember the amendment to the agreement that the contract in non-exclusive???
I believe that the 25, 35 and 40mg strengths are PAR's property whereas the 5???, 10, 15, 20, and 30mg are IPCI's property.
Can anyone offer insight into this???
I can't imagine that the Odidi's, who lent IPCI money and settled for warrants at $3.50... would not buy IPCI stock outright at under $1.00.
No insider buys... It does not make sense, unless there are negotiations going on in the background that would make it illegal insider trading on undisclosed news.
Either no one there believes in IPCI... or a possible fortune changing partnership is on the table.
As for those who think the Odidis are happy enough with collecting salaries... in rounded figures... their combined earnings are $1 million a year... they combined own 5 million shares... their combined loss when stock went from $2.80 to $.80 was $10 million $... that is equivalent to both working for free for the next 10 years to re-coup their losses.
Nov 10. 2017 numbers were
Egalet Corp. (EGLT) Halted due to pending news
2:45 pm ET November 16, 2017 (Dow Jones
http://egalet.investorroom.com/2017-11-16-Egalet-Announces-Positive-Top-Line-Results-from-Phase-3-Safety-Study-Evaluating-Safety-of-Egalet-002
MNK Seroquel XR Sales
$1.7 million 3rd Qtr 2017 Actual
$6.6 million 4th Qtr 2017 Tight Estimate
388% Qtr over Qtr growth... can't assume that kind of growth going forward... but even a 10% growth Qtr over Qtr can be a meaningful thing.
$1.7 million 3rd Qtr 2017 Actual
$6.6 million 4th Qtr 2017 Tight Estimate
********** 10% growth Qtr over Qtr ************
$7.26 million 1st Qtr 2018 Estimate
$7.98 million 2nd Qtr 2018 Estimate
$8.77 million 3rd Qtr 2018 Estimate
$9.64 million 4th Qtr 2018 Estimate
$33.55 million 2018 Sales
$38.56 million 2019 Sales with 0% growth thereafter.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136115642
We will post a message here within the next day or so... we will be staying at the South Point, but will have car available so we can meet where ever... IPCI news between now and then would be nice.
It is Sevag???